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Despite the rising risk factor exposure and non-communicable disease (NCD) mortality
across the Middle East and the North African (MENA) region, public health policy responses
have been slow and appear discordant with the social, economic and political circumstances
in each country. Good health policy and outcomes are intimately linked to a research-active
culture, particularly in NCD. In this study we present the results of a comprehensive analysis
of NCD research with particular a focus on cancer, diabetes and cardiovascular disease in
10 key countries that represent a spectrum across MENA between 1991 and 2018.
Methods
The study uses a well validated bibliometric approach to undertake a quantitative analysis of
research output in the ten leading countries in biomedical research in the MENA region on
the basis of articles and reviews in the Web of Science database. We used filters for each of
the three NCDs and biomedical research to identify relevant papers in the WoS. The coun-
tries selected for the analyses were based on the volume of research outputs during the
period of analysis and stability, included Egypt, Iran, Jordan, Kuwait, Lebanon, Oman,
Qatar, Saudi Arabia, Turkey and the United Arab Emirates.
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Results
A total of 495,108 biomedical papers were found in 12,341 journals for the ten MENA coun-
tries (here we consider Turkey in the context of MENA). For all three NCDs, Turkey’s output
is consistently the highest. Iran has had considerable growth in research output to occupy
second place across all three NCDs. It appears that, relative to their wealth (measured by
GDP), some MENA countries, particularly Oman, Qatar, Kuwait and the United Arab Emir-
ates, are substantially under-investing in biomedical research. In terms of investment on
particular NCDs, we note the relatively greater commitment on cancer research compared
with diabetes or cardiovascular disease in most MENA countries, despite cardiovascular
disease causing the greatest health-related burden. When considering the citation impact of
research outputs, there have been marked rises in citation scores in Qatar, Lebanon, United
Arab Emirates and Oman. However, Turkey, which has the largest biomedical research out-
put in the Middle East has the lowest citation scores overall. The level of intra-regional col-
laboration in NCD research is highly variable. Saudi Arabia and Egypt are the dominant
research collaborators across the MENA region. However, Turkey and Iran, which are
amongst the leading research-active countries in the area, show little evidence of collabora-
tion. With respect to international collaboration, the United States and United Kingdom are
the dominant research partners across the region followed by Germany and France.
Conclusion
The increase in research activity in NCDs across the MENA region countries during the time
period of analysis may signal both an increasing focus on NCDs which reflects general
global trends, and greater investment in research in some countries. However, there are
several risks to the sustainability of these improvements that have been identified in particu-
lar countries within the region. For example, a lack of suitably trained researchers, low politi-
cal commitment and poor financial support, and minimal international collaboration which is
essential for wider global impact.
Introduction
The social, economic and political impacts of non-communicable diseases (NCDs) are now
recognized to be some of the greatest challenges facing countries in their efforts to deliver on
Sustainable Development Goals (SDGs) and Universal Health Coverage (UHC) [1]. Whilst the
public policy dialogue has focused on communicable diseases, research into NCDs has
received little attention [2] [3].
Relative to their available economic resources, many of the Middle East and North African
(MENA) countries have not, historically, achieved good health outcomes [4]. The recent
Health Systems Reform series on health in the MENA region provided evidence of the hetero-
geneous patterns of health outcomes across this region [5]. Despite poor outcomes in conflict-
impacted countries such as Syria, Iraq, Libya, Yemen and Afghanistan over the last two
decades, child and adult mortality rates have declined across the MENA region as a whole, par-
ticularly in Saudi Arabia, Iran, Qatar, the United Arab Emirates, Oman, and Turkey [6, 7]. [8].
The MENA population most at risk of NCDs, i.e. those aged over 60, currently ranges from
0.8% in the UAE to 10.6% in Turkey [9]. These percentages are expected to increase signifi-
cantly by 2030 as a result of the demographic transition due to continuing improvements in
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life expectancy. Compounding this demographic effect, is exposure to NCDs risk factors such
as tobacco, obesity and hypertension, which is highly prevalent across the MENA region.
In Bahrain, Egypt, Jordan, Kuwait, Saudi Arabia and the United Arab Emirates, adult obe-
sity (BMI� 30) is becoming a major issue in both men and women [10], and almost 25% of
the MENA population suffers from hypertension [11]. Estimates from the Global Burden of
Disease (GBD) study show that the highest prevalence of obesity among adults 20 years or
older in 2015 was observed in Qatar, with 42.5% among males and 52.4% among females, and
in the younger population of children 2–19 years in Kuwait with 22.1% among males and
19.2% among females (GBD 2015).
Whilst tobacco use is declining worldwide, according to the World Health Organization
(WHO) Global Report on Trends in Tobacco Smoking 2000–2025, the prevalence of tobacco
smoking in the MENA region is projected to increase between 2010 and 2025 [12].
There is also wide variation in the demographic patterns of cigarette smoking, with preva-
lence among older men at 30–50% in Egypt, Jordan and Bahrain, compared to 7–15% in the
UAE and Oman [13]. Moreover, water-pipe tobacco smoking (e.g., hookah, shisha, arghile,
narguileh) is increasing among the youth in the region.
Cardiovascular disease, cancer and diabetes represent up to one third of the current disease
burden in the MENA region. The cardiovascular disease burden has remained relatively stable
between 2000 and 2015 rising from 17.5% of all DALYS to 18.9%. The burden is twice that of
Cancer, the burden of which has increased from 8.6% to 10.2% of all DALYs in the same time
period. Diabetes represented 4.3% of all DALYs in 2015, up from 2.5% in 2000.
Despite the rising risk factor exposure and NCD mortality, regional public health policy
responses have been slow. Historical and future R&D activity in NCD is foundationally depen-
dent on the knowledge economy of these countries, however, in many places this is still lagging
behind (https://gulfbusiness.com/the-middle-easts-state-of-knowledge/). In the face of the sig-
nificant public health threat from NCDs and the drive to improve health systems research and
address the knowledge gap in the MENA region, there is a need for evidence-based inter-sec-
toral measures for NCD prevention and care in the MENA region and for an understanding of
how to improve the NCD research capacity and capability across the region.
To achieve this, it is important to understand from a public policy perspective how, why,
and which particular NCD research domains have evolved. For example, how do different
countries influence the NCD research agenda, either through the volume of research they pub-
lish, the citation impact of their articles, or their commitment to particular research domains
(eg, basic science)? An empirical analysis of research outputs would also highlight gaps and
provide direction as to which research areas should be prioritized to meet current and future
challenges.
Using a bibliometric approach, we present a high resolution analysis of NCD research in
ten key “Bell weather” countries that reflect the (stable, permissive) diversity of the MENA
region between 1991 and 2018 (28 years) to characterize its breadth and depth and how these
have evolved over the course of nearly three decades. This type of analysis is now used rou-
tinely in public policy analysis to study research domains [14–17]. A bibliometric approach
allows one to understand and characterise research in the region, to provide an understanding
of the research capacity to manage this burden (workforce and time required to produce
research outputs) relative to wealth and individual disease burden. In addition, it provides a
focus for understanding areas for informing policy by providing insight into research prioriti-
sation, research impact and the extent of regional and international collaborations.
We therefore examine the growth in NCD research outputs over time, the volume of
research produced relative to the countries’ wealth, population size, and NCD disease burden.
In addition, we assess the citation impact of each country’s NCD research as well as the impact
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of intraregional and international collaborations on the volume and quality of research
outputs.
Methods
A number of different definitions for country composition of the MENA region currently exist
[18] with some including Turkey. Our analysis of NCD research activity covers the 10 major
research-active countries in this region (defined according to the volume of research outputs)
for the 28-year period between 1991 and 2018. The selected countries are: Egypt, Iran, Jordan,
Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey, and the United Arab Emirates. Interna-
tional Standards Organization (ISO) digraph codes for each country are listed in Table 1. We
excluded countries that are considered politically unstable e.g. Iraq, Yemen and Syria and did
not include smaller research producing countries such as Bahrain, Libya, Palestine, as they
would not be informative for understanding overall NCD and workforce policy in the region.
We also wished to look at broad trends of countries within a specific research-political nexus,
hence exclusion of both low output countries and specific countries in North Africa that are
not part of the intra-regional research nexus.
In addition, for each country, we cover the three most prevalent NCDs in the MENA
region: cancer, cardiovascular disease and diabetes.
Research papers (articles and reviews) from the 10 selected countries were identified from
the Web of Science (WoS) in the selected NCDs by means of three separate algorithms (filters),
developed by GL in collaboration with experts in these NCD fields (See Appendix 1). Each of
these three filters consisted of two parts: a list of specialist journals for each NCD and a list of
specific title words. There were 185 specialist journals listed for cancer, 115 for cardiovascular
disease and 36 for diabetes, and there were 323 title words or phrases used for cancer, 125 for
cardiovascular disease and 35 for diabetes. Of note the cardiovascular filter includes cerebro-
vascular accident (CVA). Each filter was independently applied to all papers identified from
each of the 10 countries within the WoS. Papers satisfying either criterion (i.e. containing a
specific NCD title word or published in an NCD specialist journal), or both, were selected for
analysis.
Each of the filters has undergone a process of calibration during the development phase to
assess their precision (specificity) and recall (sensitivity)[19]. The filters have been used previ-
ously in other analyses[14, 20, 21] and the process of development of the cancer filter for exam-
ple is listed [22]. For the three NCD domains sensitivity and specificity rates were calculated as
follow, with sensitivities and specificities above 90% considered high:
• CARDI p = 0.95, r = 0.90,
• DIABE p = 0.90, r = 0.98
• ONCOL p = 0.95, r = 0.98
Table 1. List of 10 countries from MENA region that were the focus of the study.
Country ISO Country ISO
Egypt EG Oman OM
Iran IR Qatar QA
Jordan JO Saudi Arabia SA
Kuwait KW Turkey TR
Lebanon LB United Arab Emirates AE
https://doi.org/10.1371/journal.pone.0232077.t001
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A separate filter for biomedical research was developed and also applied to the WoS [19].
The rationale for this was to provide a baseline from which the relative increases in volume of
research outputs in the three NCD domains can be considered. It also provides the relevant
context for understanding the commitment of each country across all biomedical research
domains.
This was based, not on title words, but on words in the addresses of the papers that indi-
cated the name of the department, e.g. Department of Cardiology, or the institution, such as
NIH (US National Institutes of Health). There were a total of 172 terms in this filter, and it has
been found to distinguish well between biomedical and non-biomedical papers in multi-disci-
plinary journals such as Nature and Science.
Assessment of research output relative to GDP and disease burden
An analysis was undertaken to determine whether the amount of biomedical research in each
MENA country in 2011–18 was commensurate with its overall wealth as measured by Gross
Domestic Product (GDP), and also with its respective population size (both for 2014).
The research output in each of the three NCDs was calculated as a proportion of total bio-
medical research output. A comparison was also made with the relative burden of disease,
measured in Disability Adjusted Life-Years (DALYs) attributable to each NCD. Disability
Adjusted Life Years are the sum of years of potential life lost due to premature mortality (com-
pared with life expectancy in Japan) and the years of productive life lost due to disability (e.g.
pain, loss of vision) based on how bad particular problems are.
These were calculated as percentages of DALYs attributable to all causes for each country in
the years 1990 to 2015 [23]. It was therefore possible to compare for each country the propor-
tion of research into each NCD domain relative to its total biomedical research output with
the proportion of DALYs attributable to each NCD. This was calculated for two 10-year time
periods (1996–2005 compared with DALYs in 2000 and 2009–2018, compared with DALYs in
2010) to assess what the changes in commitment had been relative to the changing disease
burden.
Contribution of basic compared with clinical research over time
The research level of the papers (RLp) was assessed for the papers in each domain, from each
country and for the two decades 1996–2005 and 2009–18. The mean research levels give an
indication of the countries’ commitment to clinical research relative to basic science within
that NCD. It is based on the presence of selected “clinical” and “basic science” words in their
titles. Groups of papers were assigned a value of RLp between 1.0 (clinical observation) and 4.0
(basic research) depending on whether their titles contained one or more of a list of “clinical
words” e.g., diagnosis, elderly, “basic words” e.g. activation, binding, chromosome, or both [24].
Impact of international collaboration on quantity and impact of research
International collaboration was assessed by calculation of the proportion of biomedical
research outputs within each of the MENA countries that had foreign addresses (a proxy for
international co-authorship) between 2011 and 2018. For this purpose, the numbers of each
country’s papers with no other country present among the addresses were determined, and
then subtracted from the total output. A further analysis revealed the extent of international
biomedical research collaboration between the selected 10 MENA countries and others in the
MENA region as well as with the top 10 biomedical research-active countries globally. The
indicator used was the Salton Index (SI). This is defined as the ratio of the numbers of joint
publications to the square root of the product of the two individual totals, multiplied by 100.
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For the biomedical research papers, the Actual Citation Impact (ACI) was calculated as the
number of citations received by a paper in the five years beginning in the year of publication.
A five-year window was used as it represents a compromise between the need for immediacy
(i.e., citations to recent papers) and stability (i.e., inclusion of the peak year for citations, usu-
ally the second or third year after publication). For the biomedical papers from 2001–2010,
ACI values were obtained from the WoS for each of the ten countries and for each publication
year. Because these scores varied from year to year, particularly for the smaller countries,
three-year running means were calculated so as to smooth out this variation.
Results
Outputs of research papers in the three NCDs
Between 1991–2018, 495,108 biomedical papers were found in 12,341 journals for the 10
MENA countries. Altogether, in cancer there were 52,911 papers in 4344 journals; in cardio-
vascular disease, there were 49,234 papers in 4382 different journals, and in diabetes there
were 13,298 papers in 2403 journals. Nearly all of the papers were in English (98.5%), but oth-
ers were in 19 different languages, led by Turkish with 1.2%.
In 2015, 17% of the diabetes papers, 18% of the oncology papers and 21% of the cardiology
papers were published in journals from eight of the selected MENA countries (all except for
Lebanon and Oman). The papers were primarily from Turkey (61% of the MENA total) and
Iran (30%): Saudi Arabia and the UAE contributed less than 4% of the MENA total. The four
leading MENA journals are all Turkish: Archives of the Turkish Society of Cardiology, Journal
of Clinical and Analytical Medicine, Anatolian Journal of Cardiology, and Turkish Journal of
Thoracic and Cardiovascular Surgery (all with between 90 and 110 papers).
The research outputs of the 10 MENA countries in the three NCDs for the years 1991–2018
are shown in S1, S2 and S3 Figs for cancer, cardiovascular research and diabetes respectively.
With few exceptions, there is a trend of increasing outputs over time in all countries for all
three NCDs, and Turkey’s (TR) output is consistently the highest. Iran (IR) has overtaken sev-
eral other countries to occupy second place across all three NCDs. Egypt’s (EG) output has
also expanded quite quickly to overtake that of Saudi Arabia (SA).
The correlation between country biomedical research outputs and wealth,
population and disease burden
During the eight years, 2011–18, the 10 MENA countries published 328,585 biomedical papers
(5.4% of the world total) in 10,855 different journals. Biomedical research activity was poorly
correlated (r2 = 0.52) with the wealth of the 10 MENA countries in 2014 (Fig 1) but much bet-
ter with their populations (r2 = 0.88) (Fig 2). In both Figs 1 and 2, the spots for Kuwait (KW),
Oman (OM) and the United Arab Emirates (AE) all lie below the regression-line, and those
for Iran (IR) and Turkey (TR) lie above the line.
The relationship between disease burden and research activity is complex, with a heteroge-
neous picture across the 10 MENA countries both within each NCD and between NCDs. With
a few exceptions, the MENA countries do more research on cancer than the burden (an aver-
age of 6.3% of all DALYs) would appear to justify. Conversely cardiovascular disease (with
15.5% of all DALYs) and diabetes (with 2.9%) appear to be under-researched.
This dynamic is illustrated in Figs 3, 4 and 5 for the three NCDs. The arrows from blue
squares (1996–2005) to red squares (2009–18) show the changes in both disease burden (per-
centage of the total DALYs) and in research output (percentage of biomedical research). One
could expect that the country-level research outputs within each NCD would be approximately
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proportional to the relevant disease burden, in which case the spots should all lie on or close to
the diagonal.
Fig 3 covers cancer research and shows that it is given significant research prioritisation rel-
ative to its disease burden in all the ten MENA countries except for Turkey (TR) in the last
decade (spots lying above the line). For several countries the commitment to cancer research
as measured by research outputs is becoming greater: Jordan (JO), the United Arab Emirates
(AE), Qatar (QA), Iran (IR) and Lebanon (LB) all had their output approximately in balance
with the burden in 1996–2005, but they did a lot more cancer research in 2009–18 despite the
burden being little changed.
Fig 1. Biomedical research outputs, 2011–18, from the ten IW countries (integer counts) compared with their gross domestic
products in 2014. Solid line is best fit to data for the 10 countries on least-squares basis. Dashed lines represent outputs half, and twice
those expected from countries’ GDP. For country codes, see Table 1.
https://doi.org/10.1371/journal.pone.0232077.g001
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Fig 4 covers cardiovascular research and shows a more mixed picture. It appears to have
relatively low research prioritisation (spots below the diagonal) relative to its health burden in
all ten MENA countries except for Qatar (QA), where it clearly was highly prioritised with
22% of total biomedical research output in 1996–2005. However, for most of the countries, the
red spots are closer to the diagonal line than the blue spots, showing that both the amount of
research has increased across the two decades (apart from in Saudi Arabia (SA), Kuwait (KW)
or Turkey (TR)) and that the relative cardiovascular disease burden is going down except in
Egypt (EG), Lebanon (LB) and Saudi Arabia (SA).
Fig 2. Biomedical research outputs, 2011–18, from the ten IW countries (integer counts) compared with their populations in
2014. Solid line is best fit to data for the 10 countries on least-squares basis. Dashed lines represent outputs half, and twice those
expected from countries’ populations. For country codes, see Table 1.
https://doi.org/10.1371/journal.pone.0232077.g002
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Fig 5 covers diabetes and shows that the burden of disease is increasing in all ten MENA
countries apart from the United Arab Emirates (AE) for which diabetes research has been a
major research priority when compared with the other nine countries during the time period
of analysis. The increase in diabetes-related disease burden is particularly marked in Saudi
Arabia (SA), Iran (IR), Oman (OM) and Turkey (TR). With respect to research outputs, Egypt
(EG), Iran (IR) Jordan (JO), and Qatar (QA) all had relatively low commitments to diabetes
research in the 1996–2005 period. However, they have increased their outputs considerably in
the recent decade, as has Kuwait (KW), reflecting its persistently high diabetes burden.
Fig 3. Graph demonstrating relative commitment of each ME country to cancer research (proportion of papers in oncology out
of total for biomedicine) compared to its diabetes specific disease burden (measured as a percentage of DALYS attributable to
oncology relative to total country-specific DALYS) for two 10-year time periods (1996–2005 and 2009–18). Arrows demonstrate
change in direction of commitment to particular NCD domain research in the two time periods. The solid diagonal line represents
exact equivalence of percentages, and the dashed lines represent values of research that are just twice, or half, the amounts
corresponding to the percentage of DALYs.
https://doi.org/10.1371/journal.pone.0232077.g003
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NCD research levels
NCD research activity is mainly clinically oriented (RL values mostly between 1.0 and 2.0).
Only Egypt appeared to do rather more basic research than the other MENA countries in the
three NCDs. Whilst cardiovascular and diabetes research outputs have become slightly more
clinical on average (see mean scores), cancer-related output has become more basic compared
to the previous decade, as exemplified by the United Arab Emirates. There has been a notice-
able shift towards basic research for oncology in Qatar. Over the two decades, research outputs
in all three NCD domains have become increasingly basic in Saudi Arabia.
Fig 4. Graph demonstrating relative commitment of each ME country to cardiology research (proportion of papers in cardiology
out of total for biomedicine) compared to its diabetes specific disease burden (measured as a percentage of DALYS attributable to
cardiology relative to total country-specific DALYS) for two 10-year time periods (1996–2005 and 2009–18). Arrows demonstrate
change in direction of commitment to particular NCD domain research in the two time periods. The solid diagonal line represents exact
equivalence of percentages, and the dashed lines represent values of research that are just twice, or half, the amounts corresponding to the
percentage of DALYs.
https://doi.org/10.1371/journal.pone.0232077.g004
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Citation Impact of MENA biomedical research outputs
Between 2001 and 2010 the mean five-year citation scores for biomedical research have been
steadily increasing in all ten MENA countries. There have been marked rises in citation scores
in Qatar (QA), Lebanon (LB), United Arab Emirates (AE) and Oman (OM). Turkey (TR),
which has the largest biomedical research output in the Middle East (Fig 1) has only achieved a
marginal increase in its citation scores over this time period, and has the lowest citation scores
overall.
Fig 5. Graph demonstrating relative commitment of each ME country to diabetes research (proportion of papers in diabetes out of
total for biomedicine) compared to its diabetes specific disease burden (measured as a percentage of DALYS attributable to
Diabetes relative to total country-specific DALYS) for two 10-year time periods (1996–2005 and 2009–18). Arrows demonstrate
change in direction of commitment to particular NCD domain research in the two time periods. The solid diagonal line represents exact
equivalence of percentages, and the dashed lines represent values of research that are just twice, or half, the amounts corresponding to
the percentage of DALYs.
https://doi.org/10.1371/journal.pone.0232077.g005
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International collaboration for the three NCD domains
We obtained the numbers of internationally co-authored research papers in the three subject
areas from each of the ten MENA countries between 2016–18. There is substantial variation in
the percentage of foreign involvement (Fig 6) with greater proportional collaboration seen in
those countries that have smaller output as exemplified by Qatar (QA), United Arab Emirates
(AE), Oman (OM) and Lebanon (LB). Conversely, it appears that those MENA countries with
larger outputs such as Iran (IR) and Turkey (TR) collaborate less internationally. This is partic-
ularly marked for Turkey (TR), with an average of only 15% foreign contribution across all
three domains of NCD research.
Fig 7 shows the relationship between international research collaboration in 2009–10 for
the ten MENA countries and the influence of their published biomedical research, as measured
by five-year citation counts in the WoS. The citation counts appear to be well correlated with the
extent of international collaboration, with those countries that have a larger proportion of their
papers co-authored with other countries having higher mean citation counts. Both Qatar (QA)
and Lebanon (LB) have higher citation scores than expected on the basis of the regression line.
We examined the amount of collaboration with countries outside the ten MENA states
between 2011–18. The Salton Index values (see methods section) for the 10 most biomedically
research-active countries are shown in Table 2. The United States and United Kingdom are
the dominant research partners across the region followed by Germany. France is notable for
its collaboration with Lebanon, and the United Kingdom for its collaboration with Qatar.
Egypt collaborates extensively with the United States and Germany. Saudia Arabia, appears to
collaborate with a number of major research active countries including, the US, UK, Canada,
Australia and India. Italy is noticeable for its collaboration with Turkey, which collaborates lit-
tle with other international partners.
We investigated which MENA countries the ten MENA countries collaborated with in the
eight years, 2011–18. Much of their international collaboration was with each other, and
Fig 6. Chart showing the percentage of research output for each IW country in the three NCD domains for 2016–18 that had at least
one international co-author.
https://doi.org/10.1371/journal.pone.0232077.g006
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Table 3 shows the Salton Index for each of the 10 MENA countries with a co-author from one
of the other nine. Both Saudi Arabia (SA) and Egypt (EG) appear to be the dominant research
collaborators across the MENA region. As well as contributing to each other’s research output
they are also key collaborators for Oman (OM), Qatar (QA), and Jordan (JO). Turkey (TR)
and Iran (IR), which are the two leading research active countries in the area, show little evi-
dence of collaboration.
Fig 7. The relationship between mean five-year citation counts (ACI) for 2009–10 biomedical research papers and the percentages of
these papers that are international for the ten IW countries.
https://doi.org/10.1371/journal.pone.0232077.g007
Table 2. Salton Indexes for each MENA country’s biomedical research papers from 2011–18 that are co-authored with one of 10 other leading countries.
AE EG IR JO KW LB OM QA SA TR
US 1.68 2.19 1.69 1.27 0.81 1.93 0.63 1.96 2.91 1.93
CN 0.55 0.93 0.56 0.27 0.23 0.39 0.45 0.74 1.52 0.60
UK 1.78 1.94 1.46 1.16 0.93 1.17 0.97 2.71 2.74 1.74
DE 1.10 2.32 1.21 0.86 0.50 0.79 0.83 1.45 1.91 1.94
JP 0.50 1.64 0.42 0.44 0.31 0.55 0.30 0.37 1.05 0.56
CA 1.36 1.31 1.49 0.87 0.86 1.36 0.69 1.32 2.54 0.84
IT 1.00 1.45 1.34 0.70 0.49 1.38 0.61 1.66 1.73 2.15
FR 1.00 1.30 0.96 0.46 0.44 3.47 0.61 1.84 1.57 1.73
AU 1.30 0.76 1.51 0.88 0.81 0.77 0.71 1.73 2.01 0.80
IN 1.47 1.35 0.90 0.56 0.43 0.59 1.61 1.20 4.56 0.88
US = United States, CN = China, UK = United Kingdom, DE = Germany, JP = Japan, CA = Canada, IT = Italy, FR = France, AU = Australia, ES = Spain, IN = India.
Cells with values > 2 tinted pale green; cells with values < 0.5 tinted pale yellow.
https://doi.org/10.1371/journal.pone.0232077.t002
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Discussion
The majority of the MENA countries have shown a rapid improvement in their health status
over the last three decades, primarily through a reduction in mortality from communicable
diseases. However, their approach to managing the ever-increasing burden of NCDs has
largely focused on a curative model with a proposed expansion of health care resources and
uptake of new technologies, rather than prevention and health promotion services [25]. It is
imperative that there is capacity building to strengthen biomedical research in the MENA
region to address the rising tide of NCDs by improving international collaboration, supporting
investment in research and training, and improving the research environment [26].
The increase in research activity in NCDs across the MENA region during the time period
of analysis may signal both an increasing focus on NCDs which reflects general global trends,
and greater investment in research in some countries. For example, in Qatar there has been a
substantial increase in research funding, $100 million over 10 years, which perhaps explains its
recent rapid improvement in research outputs and citation impact [27]. It has also sought to
align its clinical and academic health development strategies through the creation of academic
health centers and partnerships [28].
However, our analysis shows that some MENA countries, particularly Oman, Qatar, Kuwait
and the United Arab Emirates are still substantially under-investing in biomedical research
relative to their GDP. There is also continued evidence of low political commitment in the
region, poor financial support for researchers, as well as poor access to funding for NCD
research despite some major potential sources [25].
This is illustrated by the fact that 4.6% of the world’s financial resources are produced in the
Eastern Mediterranean region member states, yet the share of health research resources in the
region is only 0.6% (one-seventh of the region’s financial resources)[29]. The recent UNESCO
report estimated that the ratio of gross domestic expenditure on R&D (GERD) to GDP was
very low in the region, and has been on average 0.3%, 97% of which was provided by public
resources. The positive point observed in this report is the increase in R&D investment from a
few countries. For example, this ratio was 0.03% in Tunisia in 1996, but had reached 1% by
2000. In countries such as Iran and Egypt, there is a 5-year plan to reach 3% and 1% respec-
tively by 2012. Among the wealthier nations, Qatar has had a plan to reach 2.8% in 2011 [29].
NCD priorities in the region
In terms of investment on particular NCDs, we note the relatively greater investment on can-
cer research compared with diabetes or cardiovascular disease in most MENA countries,
Table 3. Salton Indexes for each MENA country’s international biomedical research papers from 2011–18 that are co-authored with one of the other nine. Cells
with values> 2 tinted pale green; cells with values> 5 tinted bright green.
AE EG IR JO KW LB OM QA SA TR
AE 3.2 0.8 4.4 3.8 3.7 6.3 4.6 4.1 0.8
EG 1.2 1.9 3.1 2.3 2.3 3.5 20.3 1.4
IR 0.6 0.6 0.7 0.9 1.5 1.0 1.2
JO 1.6 2.8 2.0 2.4 5.0 0.6
KW 1.9 3.1 3.2 3.0 0.5
LB 1.7 3.1 2.4 0.7
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despite cardiovascular disease causing the greatest health-related burden (GBD, 2013). In addi-
tion, the Gulf Cooperative States (Oman, UAE, Qatar) countries face a continued rise in diabe-
tes incidence, yet our findings show that, compared to their wealth, there is relatively less
research prioritisation on addressing the burden.
The research outputs across these three main NCDs are becoming increasingly clinically
focused across the last two decades. This is in contrast to findings across Europe which dem-
onstrates that some NCD outputs are moving in the opposite direction towards more basic sci-
ence research, perhaps as a result of the rising costs of clinical trials [15].
International collaboration
One mechanism for raising the profile and citation impact of research is through international
collaboration. MENA countries vary substantially in the level of intra-regional and interna-
tional collaboration. Our findings illustrate that internationally-co-authored publications
within the region included researchers predominantly from the USA, followed by the UK, Ger-
many and France. This is in keeping with other studies which have shown that approximately
45% of all multinational publications include a US author [22].
We also demonstrate a strongly positive association between international collaboration
and higher impact publications (as measured by citation counts) in the MENA region, irre-
spective of the volume of research output by individual countries. This association has been
demonstrated previously, and supports the role of international collaboration in developing a
country’s research influence and infrastructure [22].
While international collaboration may be seen as a research strength, these associations
may mask more complex underlying mechanisms. For example, in countries, such as Iran and
Turkey, which collaborate significantly less than other countries in the region but are amongst
the largest producers of biomedical research, there is greater investment in research and thus a
more developed infrastructure. As a result, researchers in these countries may choose to pub-
lish their research in regional journals with a low impact internationally in order to more effec-
tively reach local policy-makers and effect change at a local level. This mechanism may also
explain in part the low citation impact in some countries with the highest number of outputs,
but it may also reflect an international bias in favor of Western research.
There are other caveats with this type of analysis. In particular, that the notion of collabora-
tion does not guarantee that this is a partnership of equals or will necessarily result in building
research capacity and capability. This is more likely to be the case if partnership involves
merely the provision of “local” data or tissue samples for research to be done. In addition, as
well as co-authorship, collaboration may be achieved through sponsorship and funding, which
we have not specifically analyzed.
Investment in training
To build a sustainable and effective research infrastructure, and tackle NCDs across the
MENA region there is a pressing need to increase the cadre of national researchers, and health
workers [21]. On average, there are only 25 health workers per 100,000 people in countries
within the Organisation for Islamic Cooperation (OIC) (a political bloc that includes the
MENA region). This is only slightly higher than the critical threshold of 23 per 100,000 needed
to deliver basic health services and compares with 41 per 100,000 in non-OIC countries (OIC
health report 2015). Further information on the number of academic researchers would also
help to inform policy but this is currently not available.
Research seeking to understand the barriers to building research capacity, particular around
creating a skilled workforce remains limited and further investigation is required across the
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MENA region. A possible factor is that research training is generally not a focus of the educa-
tion that health workers receive and the reality is that they are often overloaded with routine
clinical work, without either the basic skills or time for research [30].
On a more general level, these countries lack the depth and breadth of higher education sys-
tems to generate a sustainable knowledge economy. In part, this is due to their relatively recent
entry into the knowledge economy; however, many countries in the region have started to
invest in their education infrastructure [31]. In addition, there is increasing awareness espe-
cially amongst national governments that there is too much dependence on international staff,
especially in the fields of science and technology. In order to nationalize the research labour
force, there has to be structural reform with the introduction of clearly defined policies that
focus on education, training, transfer of knowledge into ‘home grown’ NCD research [32].
Limitations of this study
The present study has both strengths and limitations. The analysis has been undertaken on an
individual country basis and findings with respect to country outputs are potentially skewed
depending on the size of the population and resources of individual countries. In addition,
MENA countries which conduct many collaborative multinational studies may appear to pro-
duce comparatively fewer research outputs on the basis of fractional counts, compared to Iran
and Turkey, for instance. We have used citation frequency as a proxy indicator for quality of
research and dissemination of scientific findings. However, a true evaluation of the scientific
quality of publications cannot be achieved without an independent and dedicated assessment
of their merit. Furthermore, citation frequency cannot determine whether a publication
changes practice and improves population health[33]. We also acknowledge that the propor-
tion of published studies that are trials is another mechanism for understanding the RnD infra-
structure of each country, however this was not included within our analysis.
We have selected publications available in the WoS for analysis, and it is therefore likely
that some research output in national language journals has not been included, which could
affect our results. In addition, as with any bibliometric evaluation, it is not possible to guaran-
tee inclusion of all relevant papers. However, we have allowed for the lack of precision and
recall of the three filters by making corrections to the numbers of papers.
Finally, although we examined the outputs of 10 MENA countries, our analysis may not
hold for the other countries within the region. We selected “bellweather” countries with the
highest volume of research outputs during the time-period of analysis. The additional micro-
analysis of lower research output countries would not inform the wider discussion regarding
workforce, training and investment in the region. For example, after excluding Iraq, Syria and
Yemen due to their political instability/current ongoing conflict–the next highest research pro-
ducers (according to volume of outputs) are Bahrain, Libya, Azerbaijan, Palestine, Afghanistan
whichbetween 2009–2018 produced 4343 publications (approximately 1.1% of the total when-
considering the overall total including the 10 main research active countriesn = 396,228). We
also considered the research ecosystem to enable comparison and therefore did not include
Tunisia, Morocco and Algeria which are geographically distinct north African countries who’s
regional research connections are distinct from the rest of the MENA region.
Conclusion
The increase in research activity in NCDs across the MENA region during the time period of
analysis may signal both an increasing focus on NCDs which reflects general global trends,
and greater investment in research in some countries. The analysis demonstrates heterogeneity
in research outputs relative to country wealth, population size as well as variation in
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prioritization of research into cancer, cardiovascular disease and diabetes across MENA coun-
tries, with no clear correlation with disease burden. MENA countries in this evaluation vary
greatly in the extent of their collaboration with other countries in the region and that of inter-
national partners, particularly the US and UK.
A number of MENA countries have exceptional levels of wealth which could, with the right
policy measures and public health strategies, offer an unprecedented opportunity to build vital
NCD research systems [34]. This research is expected to support research capacity building in
the region, by highlighting countries that still do not sufficiently invest in RnD relative to their
GDP, by focusing research prioritization towards high burden NCDs in the region, and by
demonstrating how research impact can be improved through international collaborations.
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